Organovo
在场
Organovo 是一家在股票代码 ONVO (US) 下上市的公司。
高管
查看带有其 9 名主要高管的组织结构图
Organovo 搜索最多的简介
高管在Organovo变化
- Jeffrey Miner, Chief Scientific Officer, 已经离开公司 (新闻发布的2023八月25号).
- Thomas Jurgensen, General Counsel, 已经离开公司 (新闻发布的2023八月25号).
创建提醒
跟踪 Organovo 的高管变动
生物技术
Organovo 拥有 2,297 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Genmab 已收购 ProfoundBio (公布2024五月23号).
- Centivo has announced the acquisition of Eden Health (公布2024五月23号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024五月20号).
生物技术 行业的其他推荐联系人
消息
Organovo 的最新新闻稿
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress | Organovo Holdings, Inc.
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo | Organovo Holdings, Inc.
- Organovo to Participate in the H.C. Wainwright Global Investment Conference | Organovo Holdings, Inc.
- Organovo Highlights FXR314 Combination Therapy Potential and Plan | Organovo Holdings, Inc.
- Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data | Organovo Holdings, Inc.
- Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates | Organovo Holdings, Inc.
- Organovo Announces FXR Program | Organovo Holdings, Inc.
- Press Releases | Organovo Holdings, Inc.
- Organovo Achieves 3D Tissue Model for Crohn’s Disease | Organovo Holdings, Inc.
- Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum | Organovo Holdings, Inc.
- View more press releases Close
通过电子邮件
